Month: February 2021

Clichy, France – February 17, 2021FULL YEAR 2020 RESULTS – GOVERNANCE2020 resilience reflects solid operating modelFY 2020 Net Sales: 1,627.9 million euros, (-12.6% on a comparative basis)FY 2020 Normalized Income From Operations: 229.1 million euros – NIFO margin: 14.1%Strong Cash generation and balance sheet129.7 million euros improvement in Working CapitalFree Cash Flow before acquisitions and disposals: 274.5 million eurosNet Cash Position: 183.9 million eurosNet income: 93.7 million euros – EPS: 2.08 euros – Normalized EPS: 3.54 eurosAccelerated and sustainable growth trajectoryLaunch of Horizon Plan – Categories reframed with increased consumer focusDjeep and Rocketbook: two acquisitions in line with Horizon plan to boost profitable growthProceeds from Clichy Headquarters disposal to be reinvested to support...

Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation Agreement aims to address disparity in access to treatments and to prioritize populations and regions that bear the greatest burden of sickle cell disease in the search for curative therapiesEffort expands on Novartis commitment to sickle cell disease, which includes a therapeutic pipeline and a holistic approach to diagnosis, treatment, and management of the disease in sub-Saharan AfricaBasel, February 17, 2021 — Novartis today announced that it has entered into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, the foundation will provide funding support for the discovery and development of a single-administration, in vivo gene therapy to cure sickle cell disease (SCD). The...

Clichy, France – 17 février 2021RESULTATS 2020 – GOUVERNANCEUne résilience qui reflète la solidité de notre modèle opérationnelChiffre d’affaires 2020 : 1 627,9 millions d’euros (-12,6 % à base comparable)Résultat d’exploitation normalisé 2020 : 229,1 millions d’euros – Marge d’exploitation normalisée : 14,1 %Forte génération de trésorerie et bilan solide129,7 millions d’euros d’amélioration du besoin en fonds de roulement Flux de trésorerie disponible avant acquisitions et cessions : 274,5 millions d’eurosSituation nette de trésorerie : 183,9 millions d’eurosRésultat net : 93,7 millions d’euros – BNPA : 2,08 euros – BNPA normalisé : 3,54 eurosVers une accélération durable de la trajectoire de croissanceLancement du plan Horizon – Nos catégories repensées avec une plus grande attention portée aux consommateursDjeep...

           SOLID PERFORMANCESKERING READY TO LEVERAGE THE REBOUNDConsolidated revenue: €13,100.2 milliondown 17.5% reported and 16.4% comparableRecurring operating income: €3,135.2 millionRecurring operating margin: 23.9%Net income attributable to the Group: €2,150.4 millionRecurring net income attributable to the Group1: €1,972.2 millionRecommended ordinary dividend stable at €8.00 per share Kering Press release – Full year results 2020_17 02 2021 « In a year of disruption, Kering demonstrated remarkable resilience and agility. We achieved a solid top-line recovery in the second half, we protected our margins while continuing to invest in our Houses and growth platforms, our cash flow generation remained elevated, and we further strengthened the Group’s financial structure. This year, safeguarding the health and safety of our employees...

           SOLIDES PERFORMANCES 2020KERING, RENFORCÉ, PRÊT À TIRER PARTI DE LA REPRISEChiffre d’affaires du Groupe : 13 100,2 M€-17,5% en données publiées, -16,4% en comparableRésultat opérationnel courant : 3 135,2 M€Marge opérationnelle courante à 23,9%Résultat net part du Groupe : 2 150,4 M€Résultat net part du Groupe récurrent1 : 1 972,2 M€Dividende ordinaire proposé stable, à 8,00 €Kering Communiqué – Résultats annuels 2020_17 02 2021« Dans une année de bouleversements, Kering a fait preuve d’une grande résilience et d’une remarquable agilité. Nos ventes ont affiché une reprise encourageante au cours du second semestre ; nous avons protégé nos marges tout en continuant à investir dans nos Maisons et dans nos plateformes de croissance ; notre génération de cash-flow est restée élevée et nous avons encore consolidé la structure...

Flex LNG Fourth Quarter 2020 PresentationPlease find enclosed the presentation of Flex LNG Ltd.’s fourth quarter 2020 results to be held through webcast/conference call February 17, 2021 at 3:00 p.m. CET (9:00 a.m. EST)Attend by Webcast:Use to the follow link prior to the webcast:https://edge.media-server.com/mmc/p/4edp4bzzAttend by Conference Call:Applicable dial-in telephone numbers are as follows:Norway: +47 210 33 922United Kingdom: +44 (0) 203 0095 709United Kingdom (local): 0844 493 6766United States, New York: +1 646 787 1226United States: +1 866 280 1157Confirmation Code: 5258465The presentation material which will be used in the teleconference/webcast can be downloaded on www.flexlng.com and replay details will also be available at this website.AttachmentFLNG_Q4-2020_Presentation_vF

MARSEILLE, France, Feb. 17, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conference:10thAnnual SVB Leerink Global Healthcare ConferenceEvent Date: February 24-26, 2021Fireside Chat: February 24, 2021 at 2:00-2:30 p.m. CET / 8:00-8:30 a.m. ETA live webcast of the fireside chat will be available through the News & Events page of the Investors section of the Company’s website at www.innate-pharma.com. An archived replay of the webcast will be available for approximately 90 days following the presentation.About Innate Pharma:Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving...

Marseille, Feb. 17, 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conference:      ·10th Annual SVB Leerink Global Healthcare Conference            Event Date: February 24-26, 2021            Fireside Chat: February 24, 2021 at 2:00-2:30 p.m. CET / 8:00-8:30 a.m. ETA live webcast of the fireside chat will be available through the News & Events page of the Investors section of the Company’s website at www.innate-pharma.com. An archived replay of the webcast will be available for approximately 90 days following the presentation.                                                                                                                     About...

Marseille, 17 févr. 2021 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que des membres de son équipe de direction seront présents pour une présentation durant la conférence investisseur suivante :      ·10ème conférence annuelle SVB Leerink Global Healthcare            Date : du 24 au 26 février 2021            Réunion (Fireside Chat) : 24 février 2021 de 14h00 à 14h30 CET / 8h00 à 8h30 ETUne diffusion en direct de la présentation sera accessible via la page « Evènements » de la rubrique investisseurs sur le site internet de la Société www.innate-pharma.com. Une rediffusion sera disponible pendant environ 90 jours.À propos d’Innate Pharma :       Innate Pharma S.A. est une société de biotechnologies au stade clinique, spécialisée...

Norwegian Finans Holding (the NFH Group) reported profit after tax in the fourth quarter of 2020 of NOK 436.2 million, compared with NOK 500.6 million in the third quarter. The decrease is mainly caused by loss on securities and currencies, higher provision for loan losses and lower interest income, partly offset by dividend received and lower interest expenses from deposit accounts. Return on equity was 16.4%, compared with 19.6% in the third quarter. The return on assets was 2.7%, compared with 3.2% in the previous quarter.The NFH Group’s profit after tax for 2020 amounted to NOK 1 887 million, compared with NOK 1 981 million for the same period in 2019. The decrease in profit is mainly due to higher provision for loan losses related to the uncertain outlook of COVID-19, lower net commission income due to lower credit card activity which...